SBIR/STTR Research Award

Novel assay for ubiquitin pathway enzymes as biomarkers

Award identifier 6f77ac7f1d859d9ff5ee3976f3d329d8f44ed23595ba7b5d3e2c20e4a027741dAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$267,299

Program and phase

SBIR · Phase I

Award year

2008

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
LIFESENSORS, INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
ECPPNPPB5U31
Solicitation number
PHS2007-2
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): It has been well established that the ubiquitin pathway plays an important role as a key regulator of neuronal biology. The ubiquitin pathway enzymes are essential and critical mediators of synaptic adaptability in matu re neurons, and dysfunctional ubiquitin pathway enzymes or regulation is associated with diverse neurodegenerative disorders. Deubiquitinating enzymes, or DUBs belong to a family of ~100 primarily single subunit proteins that remove ubiquitin from lysine r esidues of target proteins. Evidence suggests that that dysregulated or un-regulated DUB(s) can lead to neurodegenerative disease. Most commonly used assays for DUB activity are not suitable for either clinical applications or drug discovery. In this propo sal, a novel assay for the DUB family of proteins will be developed. The assay involves a semi-synthetic approach to develop reagents that are extensions of the C-terminus of ubiquitin that is conjugated to target proteins. A library of peptides can be ext ended from the C-terminus of ubiquitin; the best reagent for a given DUB can be selected from the library since classes of DUBs show different specificity preferences. In contrast to their fate in solution phase assays, entities cleaved by DUBs will be imm obilized on a surface, allowing them to be suitable reagents for immobilized DUBs in a multiplex environment. Since the assay can identify a protein as a DUB, it can also uncover DUB interactive proteins or the accumulation of ubquitinated substrates commo n in neurodegenerative diseases. Thus, the assay will be useful for diagnostic as well as drug discovery purposes. In Phase II, the assay will be expanded to include all known DUBs. The commercial application of this technology is the generation of product s for diagnostic and therapeutic uses as applied to DUB-linked medical needs such as neurodegenerative diseases. Proteins modified by another small protein called ubiquitin are key regulators of neuronal biology. Enzymes that catalyse the addition or remov al of ubiquitin to target proteins are important regulators of neuronal cell function and are potentially useful for diagnosing various neurological diseases or discovering drugs to treat the diseases. PUBLIC HEALTH RELEVANCE: LifeSensors proposes to devel op an assay for one of the major types of ubiquitin pathway enzymes known as DUBs (deubiquitinating enzymes). This assay represents a novel technology that will have potential utility in diagnostics and in the discovery of potent and selective drugs to tre at Alzheimer's Disease and other neurological diseases.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

40 SBIR/STTR records share this UEI (1989–2024). Reported award amounts total $22,492,305. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services, Department of Defense

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.